Sino Biopharmaceutical Limited (SBP Group) disclosed that it repurchased 10.00 million ordinary shares on 22 October 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices ranging between HKD 4.955 and HKD 4.98, with a volume-weighted average of HKD 4.9778, for a total consideration of HKD 49.78 million.
The company confirmed that all 10.00 million shares will be cancelled. Combined with earlier buybacks of 9.00 million shares on 1 September, 7.40 million on 13 October and 8.00 million on 14 October, a total of 34.40 million shares are pending cancellation. These pending cancellations represent approximately 0.18 % of SBP Group’s current issued share capital of 18.68 billion shares.
Including the latest transaction, SBP Group has repurchased 45.95 million shares under the general mandate approved on 17 June 2026, utilising 0.25 % of the 1.87 billion shares authorised for buyback. The company is restricted from issuing new shares or transferring any treasury shares until 13 November 2026, in accordance with Hong Kong Stock Exchange rules.
SBP Group’s total number of issued shares remains unchanged at 18.68 billion as of 22 October 2026, as the recently repurchased shares had not yet been cancelled at the reporting date.
Comments